You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Ultra-low Fouling and Anti-infective and Anti-thrombotic Nitric Oxide Releasing Intravascular Catheters

    SBC: NYTRICX INC            Topic: NHLBI

    Abstract Nytricx is developing a new class of Nitric Oxide (NO)-releasing intravascular medical catheters to combat infection and thrombosis associated with indwelling vascular catheters. NO gas is a natural anti-infective and anti-thrombotic human product principally released from blood vessels and immune cells. Nytricx NO-releasing technology to the catheter surfaces via a polymer matrix, mimics ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Multispectral Sensor for Chemical Composition Analysis of Ultrafine Aerosols in Air Quality Assessment

    SBC: SPECTREE INC.            Topic: R

    Project SummaryWe propose developing and validating a novel platform technology that combines the collection and chemical analysis of ultrafine particles using an in-situ multispectral technique. The sample, collected directly onto the analysis substrate, is analyzed via excitation-emission matrix (EEM) spectroscopy. This approach will be validated against laboratory combustion-generated aerosols, ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. An Interactive Education Program to Reduce High Risk Behavior in Adolescents

    SBC: KLEIN BUENDEL, INC.            Topic: NICHD

    Internet-based TRAC (i-TRAC): Interactive Emotion Regulation Skills Training to Improve AdolescentSexual Health Adolescence is a critical developmental period during which behavioral patterns are formed that have powerful influences on current and future health. This is particularly true for sexual behavior, which is affected by the biological changes of puberty as well as normative developmental ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma

    SBC: ROCK IMMUNE LLC            Topic: 102

    Abstract Cutaneous T-cell lymphoma (CTCL) is a type of extra-nodal non-Hodgkin’s lymphoma characterized by skinlesions resulting from infiltration of malignant T lymphocytes. Mycosis fungoides and Sezary syndrome are thetwo most common types of CTCL. Although treatments exist, they are mainly palliative with low response anddurability of response without any cure. The objective response rate rem ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Novel hand hygiene product to remove Clostridioides difficile spores

    SBC: Novaflux Inc.            Topic: NIAID

    7. Project Summary/AbstractC. difficile now causes more hospital-onset infections and deaths in the US than any other pathogen and is the most important cause of healthcare-associated diarrhea among adults in industrialized countries. In 2017, there were an estimated 462,100 combined healthcare- and community-associated C. difficile infection cases in the US, and 20,500 in-hospital deaths. In a ra ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. LIGHTSITE IIIB: Clinical Evaluation of Photobiomodulation (PBM) in dry AMD Patients

    SBC: LUMITHERA INC            Topic: NEI

    ABSTRACT As the population continues to age, degenerative ocular diseases become increasingly common and create tremendous burden on the health care system. Age-related macular degeneration (AMD) is a progressive ocular disease that causes visual impairment and blindness in its most advanced form and is characterized by loss of function and cell death in the macula, a central and critical part of ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Novel drug combinations for improving survival from acute radiation syndrome when administered 48 hours post- irradiation

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    Abstract. Bone marrow is one of the most radiation-sensitive tissues, and patients acutely exposed to total body irradiation (TBI) doses rt 2 Gy develop severe neutropenia, thrombocytopenia, anemia, and lymphopenia within days to weeks of exposure, often dying from infections (due to a lack of neutrophils) and uncontrolled bleeding (insufficient platelets) (referred to as the hematopoietic acute r ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. SensiTrak: Automated Assessment of Forelimb Sensation

    SBC: VULINTUS, INC            Topic: NINDS

    Project Abstract Current common methods for measuring somatosensory function in preclinical rodent models generally rely on withdrawal responses to uncomfortable or painful stimuli. These tests can be stressful to the animal, while also yielding a high variability in measured responses, and repetitive testing in longitudinal models may even result in chronic pain states. To better understand the c ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Comparative testing of tatCN19o for neuroprotection in rodent tMCAo

    SBC: NEUREXIS THERAPEUTICS, INC.            Topic: NINDS

    Project Summary/Abstract Focal cerebral ischemia (stroke) afflicts nearly 800,000 Americans each year and often results in permanent cognitive impairment or death. Efforts in developing a cerebroprotective stroke therapy have largely resulted in disappointment: the only approved pharmacological therapy is hemolytic treatment with tissue plasminogen activator (tPA; alteplase). In this project, we w ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. End to End, Cold Chain Validation Using Sample Attached History Log

    SBC: BIOTILLION LLC            Topic: OD

    Abstract Regenerative medicine therapies of various kinds are promising and rapidly growing, both in scale and type. The therapeutic products are not pills–they are living cells that are harvested from a patient (or sometimes a cell bank) and are shipped to a pharmaceutical company that modifies the cells and then sends them back to be re- injected into the patient. Logistics plays an outsize r ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government